Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease
2009 (English)In: Journal of Alzheimer's Disease, ISSN 1387-2877, Vol. 16, no 3, 649-656 p.Article in journal (Refereed) Published
Preclinical and clinical studies gave evidence that lithium could be useful in the treatment of Alzheimer's disease (AD). In experimental investigations, lithium induces brain-derived neurotrophic factor (BDNF). Recent studies have found a decrease of BDNF in the serum and brains of AD patients with potentially consecutive lack of neurotrophic support. We assessed the influence of a lithium treatment on BDNF serum concentration in a subset of a greater sample recruited for a randomized, single-blinded, placebo-controlled, parallel-group multicenter 10-week study, investigating the efficacy of lithium treatment in AD patients. In AD patients treated with lithium, a significant increase of BDNF serum levels, and additionally a significant decrease of ADAS-Cog sum scores in comparison to placebo-treated patients, were found. Diminution of cognitive impairment was inversely correlated with lithium serum concentration. Upregulation of BDNF might be part of a neuroprotective effect of lithium in AD patients. The results of the present investigation encourage performing studies with longer treatment phases to observe potential positive long-term effects of lithium in AD patients.
Place, publisher, year, edition, pages
2009. Vol. 16, no 3, 649-656 p.
Alzheimer’s disease, brain-derived neurotrophic factor, lithium, neuroprotection, neurotrophic effect, placebocontrolled trial
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-123186DOI: 10.3233/JAD-2009-1004ISI: 000264289000022PubMedID: 19276559OAI: oai:DiVA.org:uu-123186DiVA: diva2:312679